HomePeptide encyclopedia › Adipotide (FTPP)

Adipotide (FTPP): what it is and what the evidence says

An experimental peptide studied for its relationship with adipose-tissue vascularization and fat reduction in preclinical models.

Metabolic Preclinical evidence only 5 verified references No dosages
PX PeptiXtreme editorial team · Grupo VidaXtreme
Last reviewed: August 16, 2026 · How we verify this
How to read this page. It is written so you can check it: every claim about evidence hangs from a reference with its PubMed identifier, and we state just as plainly what is known and what is not. You will not find dosages or protocols anywhere on this site.

The ground it plays on

Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilising stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.

What it is studied for

Fat reduction (experimental context).

There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.

What the human evidence says

There is no published clinical trial in humans: all the evidence comes from animal models, mainly obese mice and rhesus monkeys.

The limitation that matters most

In the primate study, dose-dependent kidney toxicity was observed. Its mechanism consists of triggering apoptosis of the vasculature of fat tissue — destroying blood vessels — which amounts to a serious and uncharacterized risk in humans.

Regulatory status

Not approved. No clinical development.

Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.

Cautions and context

Mostly preclinical research; safety profile not well characterized.

An experimental compound; professional assessment is essential before any consideration.

This is not medical advice. Any decision about a compound in this encyclopedia belongs to a healthcare professional who knows your history, what you already take and your specific situation. If something you are using produces a new symptom, that is not something to observe — it is something to consult.

What this page cannot give you

A reference page can take you this far. You know what Adipotide (FTPP) is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:

That is what the course is for

PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.

See the course → Or measure your judgment, free

References

Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.

  1. Reversal of obesity by targeted ablation of adipose tissuepreclinical Nat Med · 2004 · PMID 15133506 →
  2. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeyspreclinical Sci Transl Med · 2011 · PMID 22072637 →
  3. Comment on 'a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys'review Sci Transl Med · 2012 · PMID 22539771 →
  4. Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endotheliumpreclinical Diabetes · 2012 · PMID 22733798 →
  5. A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medicationpreclinical J Control Release · 2013 · PMID 23871959 →

Was this page useful?

Research moves, and when something relevant changes we update the page. If you want to hear about it for Adipotide (FTPP) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.

Frequently asked questions

What is Adipotide (FTPP)?

An experimental peptide studied for its relationship with adipose-tissue vascularization and fat reduction in preclinical models. It is studied within the area of metabolic.

Is there human evidence for Adipotide (FTPP)?

There is no published clinical trial in humans: all the evidence comes from animal models, mainly obese mice and rhesus monkeys.

Is it approved by any health agency?

Not approved. No clinical development.

What is the dose of Adipotide (FTPP)?

We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.

Where can I learn to evaluate this properly?

This page tells you what Adipotide (FTPP) is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.

Other metabolic compounds

TesamorelinaVisceral fatAOD-9604Body compositionMOTS-cMetabolic efficiencyTirzepatidaAppetite controlRetatrutidaMetabolic regulationSemaglutidaAppetite control

← See the full encyclopedia (75 compounds)